The University of Southampton
University of Southampton Institutional Repository
Warning ePrints Soton is experiencing an issue with some file downloads not being available. We are working hard to fix this. Please bear with us.

Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation

Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation
Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation
The aim of this health technology assessment is to assess the clinical-effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C.

Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of moderate to severe hepatitis C was appraised by NICE in 2004 (TA751) and an appraisal specifically for mild hepatitis C was carried out in 2006 (TA1062). Both appraisals were based on independent assessment reports conducted by SHTAC.3,4

Since NICE's clinical guidance was published, there have been extensions to the licences for peginterferon alfa-2a and -2b. This health technology assessment is a part-review of the current NICE guidance and will be restricted to the patient subgroups that are affected by the licence extensions for the peginterferons. This includes people who have been previously treated with peginterferon alfa and ribavirin in combination and who either did not respond or who responded but relapsed, people who meet the licensed criteria for receiving shortened courses of combination therapy and people with HCV/HIV co-infection

The HTA Programme commissioned this technology assessment report on behalf of the National Institute for Health and Clinical Excellence.
1366-5278
i-210
Hartwell, D.
8ee30d05-c758-4d82-9e40-f977cd45bd58
Jones, J.
270b303b-6bad-4be7-8ea0-63d0e8015c91
Baxter, L.
eeafbfe7-ae7e-421f-a6b6-c6d9df80b6ef
Shepherd, J.
dfbca97a-9307-4eee-bdf7-e27bcb02bc67
Hartwell, D.
8ee30d05-c758-4d82-9e40-f977cd45bd58
Jones, J.
270b303b-6bad-4be7-8ea0-63d0e8015c91
Baxter, L.
eeafbfe7-ae7e-421f-a6b6-c6d9df80b6ef
Shepherd, J.
dfbca97a-9307-4eee-bdf7-e27bcb02bc67

Hartwell, D., Jones, J., Baxter, L. and Shepherd, J. (2011) Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technology Assessment, 15 (17), i-210. (doi:10.3310/hta15170).

Record type: Article

Abstract

The aim of this health technology assessment is to assess the clinical-effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C.

Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of moderate to severe hepatitis C was appraised by NICE in 2004 (TA751) and an appraisal specifically for mild hepatitis C was carried out in 2006 (TA1062). Both appraisals were based on independent assessment reports conducted by SHTAC.3,4

Since NICE's clinical guidance was published, there have been extensions to the licences for peginterferon alfa-2a and -2b. This health technology assessment is a part-review of the current NICE guidance and will be restricted to the patient subgroups that are affected by the licence extensions for the peginterferons. This includes people who have been previously treated with peginterferon alfa and ribavirin in combination and who either did not respond or who responded but relapsed, people who meet the licensed criteria for receiving shortened courses of combination therapy and people with HCV/HIV co-infection

The HTA Programme commissioned this technology assessment report on behalf of the National Institute for Health and Clinical Excellence.

Text
__userfiles.soton.ac.uk_Users_nsc_mydesktop_155443jones.pdf - Version of Record
Restricted to Repository staff only
Request a copy

More information

Published date: April 2011
Organisations: Other

Identifiers

Local EPrints ID: 155443
URI: http://eprints.soton.ac.uk/id/eprint/155443
ISSN: 1366-5278
PURE UUID: edd522c3-a64c-44ac-9827-197ee91969b3
ORCID for J. Shepherd: ORCID iD orcid.org/0000-0003-1682-4330

Catalogue record

Date deposited: 28 May 2010 13:20
Last modified: 20 Nov 2021 02:38

Export record

Altmetrics

Contributors

Author: D. Hartwell
Author: J. Jones
Author: L. Baxter
Author: J. Shepherd ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×